Anti-Acetyl-NFKB p65 (Lys314/Lys315) Antibody (2I562) is a Mouse antibody targeting Acetyl-NFKB p65 (Lys314/Lys315). Anti-Acetyl-NFKB p65 (Lys314/Lys315) Antibody (2I562) can be used in IHC-P,IHC-Fr,IF.

IgG

2I562

Human,Mouse,Rat

1. Paraformaldehyde-fixed, paraffin embedded (Mouse lung); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30 min; Antibody incubation with (Acetyl NF kB P65 (Lys314/Lys315)) Monoclonal Antibody, Unconjugated (ascites of TMAB-09435 4B11) at 1: 2000 overnight at 4°C, followed by operating according to SP Kit (Mouse) instructions and DAB staining.
2. Paraformaldehyde-fixed, paraffin embedded (Human ovarian cancer); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30 min; Antibody incubation with (Acetyl NF kB P65 (Lys314/Lys315)) Monoclonal Antibody, Unconjugated (ascites of TMAB-09435 4B11) at 1: 2000 overnight at 4°C, followed by operating according to SP Kit (Mouse) instructions and DAB staining.
3. Paraformaldehyde-fixed, paraffin embedded (Mouse colon); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30 min; Antibody incubation with (Acetyl NF kB P65 (Lys314/Lys315)) Monoclonal Antibody, Unconjugated (ascites of TMAB-09435 4B11) at 1: 2000 overnight at 4°C, followed by operating according to SP Kit (Mouse) instructions and DAB staining.
4. Paraformaldehyde-fixed, paraffin embedded (Human cervical cancer); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30 min; Antibody incubation with (Acetyl NF kB P65 (Lys314/Lys315)) Monoclonal Antibody, Unconjugated (ascites of TMAB-09435 4B11) at 1: 2000 overnight at 4°C, followed by operating according to SP Kit (Mouse) instructions and DAB staining.
5. Paraformaldehyde-fixed, paraffin embedded (Rat colon); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30 min; Antibody incubation with (Acetyl NF kB P65 (Lys314 Lys315)) Polyclonal Antibody, Unconjugated (TMAB-09435-4B11) at 1:500 overnight at 4°C, followed by a conjugated secondary for 20 minutes and DAB staining.

IHC-P: 1:100-500; IHC-Fr: 1:100-500; IF: 1:100-500

Monoclonal

KLH conjugated Synthesised acetylpeptide: human NFKBp65 around the acetylation site of Lys314/315

Human

RELA

Transcription factor p65

NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and p65-c-Rel complexes are transcriptional activators. The NF-kappa-B p65-p65 complex appears to be involved in invasin-mediated activation of IL-8 expression. The inhibitory effect of I-kappa-B upon NF-kappa-B the cytoplasm is exerted primarily through the interaction with p65. p65 shows a weak DNA-binding site which could contribute directly to DNA binding in the NF-kappa-B complex. Associates with chromatin at the NF-kappa-B promoter region via association with DDX1.